Cite
Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy: Follow-Up of the Ritux 3 Trial.
MLA
Tedbirt, Billal, et al. “Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy: Follow-Up of the Ritux 3 Trial.” JAMA Dermatology, vol. 160, no. 3, Mar. 2024, pp. 290–96. EBSCOhost, https://doi.org/10.1001/jamadermatol.2023.5679.
APA
Tedbirt, B., Maho-Vaillant, M., Houivet, E., Mignard, C., Golinski, M.-L., Calbo, S., Prost-Squarcioni, C., Labeille, B., Picard-Dahan, C., Chaby, G., Richard, M.-A., Tancrede-Bohin, E., Duvert-Lehembre, S., Delaporte, E., Bernard, P., Caux, F., Alexandre, M., Musette, P., Ingen-Housz-Oro, S., & Vabres, P. (2024). Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy: Follow-Up of the Ritux 3 Trial. JAMA Dermatology, 160(3), 290–296. https://doi.org/10.1001/jamadermatol.2023.5679
Chicago
Tedbirt, Billal, Maud Maho-Vaillant, Estelle Houivet, Claire Mignard, Marie-Laure Golinski, Sébastien Calbo, Catherine Prost-Squarcioni, et al. 2024. “Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy: Follow-Up of the Ritux 3 Trial.” JAMA Dermatology 160 (3): 290–96. doi:10.1001/jamadermatol.2023.5679.